Article
Generation of a panel of mutants that are resistant to standard of care therapies in a clinically relevant strain of human cytomegalovirus for drug resistance profiling.
Antiviral research - 1 Sept 2025
Carter Meghan F, Knight Kassidy, Kayode Yetunde, Murphy Eain A
Abstract excerpt
Infection with human cytomegalovirus (HCMV) can result in a significant disease burden within the immunosuppressed and immunocompromised patient populations. Current standard of care (SOC) relies on direct-acting antivirals which target a limited group of viral proteins including the viral polymerase (UL54), terminase (UL56), and protein kinase (UL97). Incomplete inhibition of virally encoded proteins result in a...
Topics
- Cytomegalovirus
- Humans
- Drug Resistance, Viral
- Antiviral Agents
- Mutation
- Virus Replication
- Cytomegalovirus Infections
- Standard of Care
- Ribonucleosides
- Ganciclovir
- Microbial Sensitivity Tests